AD-01 has demonstrated potent anti-angiogenic and anti-CSC activity potentially through binding to CD44.21,23 Furthermore, FKBPL and its peptide derivatives inhibit breast cancer metastasis through Notch signalling.26 Analysis of the structure, activity and stability of AD-01 led to the selection of ALM201, a 23-residue peptide as the clinical drug candidate. The gene discussed is FKBPL; the disease is breast cancer.